Drug eluting stents: maximising benefit and minimising cost.
A policy of selective implantation of drug eluting stents, in a minority of lesions most likely to benefit, seems to be a rational way to employ this new and currently costly technology.
Gunn
J
J
Cardiovascular Research Group, Division of Clinical Sciences (Northern General Hospital), University of Sheffield, Sheffield, UK.J.Gunn@Sheffield.ac.uk
Morton
A C
AC
Wales
C
C
Newman
C M H
CM
Crossman
D C
DC
Cumberland
D C
DC
D023903:Coronary Restenosis / Q000191:economics / Q000517:prevention & control*; D017046:Cost Savings; D003365:Costs and Cost Analysis; D003657:Decision Making; D004343:Drug Implants / Q000009:adverse effects / Q000191:economics; D004867:Equipment Design; D006801:Humans; D018570:Risk Assessment; D012307:Risk Factors; D015607:Stents / Q000009:adverse effects / Q000191:economics
D004343:Drug Implants